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Background: Prostate cancer disproportionately affects low-income and minority men. This study evaluates the
impact of a patient navigation intervention on timeliness of diagnostic resolution and treatment initiation among
veterans with an abnormal prostate cancer screen.
Methods: Participants were enrolled between 2006 and 2010. The intervention involved a social worker and lay
health worker navigation team that assisted patients in overcoming barriers to care. For navigated (n = 245) versus
control (n = 245) participants, we evaluated rates of diagnostic resolution and treatment and adjusted for race, age,
and Gleason score.
Results: Of 490 participants, 68% were African American, 47% were ≥ 65 years old, and 35% had cancer. Among
those with an abnormal screen, navigation did not have a significant effect on time to diagnostic resolution
compared to controls (median days of 97 versus 111; adj. HR 1.17, 95% CI, 0.96-1.43, p = 0.12). On analysis of the
period beyond 80 days, navigated men reached resolution faster than controls (median of 151 days versus
190 days; adj. HR 1.41, 95% CI, 1.07-1.86, p = 0.01). Among those with cancer, navigation did not have a significant
effect on time to treatment initiation compared to controls (median of 93 days versus 87 days; adj. HR 1.15, 95% CI,
0.82-1.62, p = 0.41).
Conclusion: Our navigation program did not significantly impact the overall time to resolution or treatment for
men with prostate cancer compared to controls. The utility of navigation programs may extend beyond targeted
navigation times, however, and future studies focusing on other outcomes measures are therefore needed.Background
Prostate cancer accounts for 28% of newly diagnosed
cancers and is the second leading cause of cancer-
related deaths among men in the United States [1]. Al-
though prostate cancer screening remains controversial,
five-and ten-year relative survival rates are highly favor-
able if prostate cancer is detected early [2]. Over the past
20 years, prostate cancer death rates have declined con-
siderably, but progress has not been equally shared
among all populations [1]. In particular, low-income men
have increased risk of distant-stage prostate cancer [3],* Correspondence: m-simon2@northwestern.edu
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reproduction in any medium, provided the orand African Americans have the highest prostate cancer
mortality rate of any racial or ethnic group in the U.S. [4].
Multiple factors have been associated with delayed
prostate cancer diagnosis, including health care system
and physician distrust [5,6], lower household incomes [7],
cancer misinformation [8], provider failure to facilitate
timely follow-up [9], and culturally-influenced resistance
to digital rectal examination (DRE) [10]. Patient naviga-
tion, a patient-centered intervention seeking to remove
barriers to timely healthcare services [11], is one possible
strategy for improving cancer outcomes–particularly
among historically disadvantaged populations. In the
1990s, Dr. Harold Freeman established the first patient
navigation program for low-income minority women in
Harlem, New York. The findings suggested that navigation
may increase rates and timeliness of diagnostic resolution
following an abnormal breast cancer screening finding
[12]. Based on the promising benefits of this model, theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cer Health Disparities (CRCHD) and American Cancer
Society (ACS) funded nine sites for the Patient Navigation
Research Program (PNRP) [13], the first multi-center
study to critically examine and demonstrate the efficacy of
navigation [14-19].
Most navigation programs have emerged in outpatient
clinical settings and have focused on breast, cervical, or
colorectal cancer; few have reported on prostate cancer
outcomes [11,20-25]. Only one nurse navigation pro-
gram has evaluated time to treatment initiation at a
Veterans Affairs (VA) hospital, but used historical con-
trols and found it challenging to isolate the effects of
navigation from other systems changes simultaneously
implemented within a larger VA process improvement
project [26]. One combined prostate cancer education
and navigator program demonstrated increased prostate
cancer screening rates among African Americans [27],
and a PNRP site reported navigation’s effect on diagnos-
tic resolution of a prostate screening abnormality [19].
In the Chicago PNRP, we uniquely implemented a naviga-
tion intervention among predominantly low-income and
minority men at a VA, where access to care barriers are di-
minished. We evaluated time to diagnostic resolution and
treatment initiation among navigated versus control pa-
tients with an abnormal prostate cancer screen.
Methods
Setting
The study took place at a Chicago VA, an equal access
system in an urban medical district. The tertiary care fa-
cility and its four community-based outpatient clinics
provide care to approximately 58,000 veterans in Chicago,
the county (Cook) in which Chicago resides, and six coun-
ties in northwestern Indiana. A large proportion of vet-
erans in Illinois are African American, and nearly half in
Cook County are over age 65 [28].
Study design
Our protocol has been described in detail previously
[29]. Briefly, the study used a quasi-experimental design.
Eligible patients were identified through electronic med-
ical records. Patients were selected to receive navigation
if they met inclusion criteria and presented to the ur-
ology clinic on a clinic day designated for the navigation
intervention (n = 245). All patients who presented on a
clinic day designated for non-navigation and met inclu-
sion criteria were identified as controls. Control subjects
received usual care and comprised a consecutive and
concurrent records-based sample with a one-to-one
match goal (n = 245). The clinic was staffed with rotating
resident physicians and stable supervising attending phy-
sicians and nurses who remained constant across navi-
gated and non-navigated clinic days.Eligibility and recruitment
Our study enrolled patients from November 2006
through April 2010. All patients who presented to the
VA urology clinic for follow-up of an abnormal prostate
cancer screening test (prostate specific antigen (PSA) ≥
4.0 ng/mL, PSA < 4.0 ng/mL with an abnormal PSA vel-
ocity defined by a physician, or abnormal DRE) and who
were recommended for a biopsy were eligible. We ex-
cluded patients if they were less than age 18, institution-
alized, cognitively impaired, previously navigated for an
abnormal cancer finding, or treated for any cancer ex-
cept non-melanoma cancer within the past five years.
Our study team approached patients for participation
following provider referral on the first follow-up visit in
the urology clinic. We obtained written informed consent
from navigated patients, and the Institutional Review
Board (IRB) granted a waiver of authorization for our con-
trol sample. The Northwestern University IRB, Jesse
Brown VA Medical Center, and the Collaborative IRB at
the University of Illinois at Chicago approved the study.
Patient navigation
The patient navigation team comprised two full-time
male navigators: one social worker and one lay health
worker [29]. Navigators participated in local training,
monthly state-level ACS trainings, and national annual
PNRP training conferences relative to navigator roles,
health disparities, cancer knowledge, cultural diversity,
and communication [30].
Upon enrollment, navigators conducted face-to-face
interviews with patients to identify potential barriers to
care, and follow-up assistance occurred in person or
over the phone until diagnostic resolution for those
without prostate cancer, primary therapy completion for
those with cancer, or until the end of the study. The
number of contacts varied according to need, but at
minimum, each patient received appointment reminder
calls one month and ten days prior to his scheduled bi-
opsy appointment to ensure compliance with prepara-
tory instructions [29]. Additional navigation activities
included social support, facilitation of patient-provider
communication, transportation coordination, and patient
education. Navigators also often accompanied patients
with prostate cancer to treatment appointments and
connected each with a cancer survivor through an
established ACS program.
Data collection
We collected self-reported demographic data at baseline
in the navigated arm and obtained them through chart
audit in the control arm. Navigators documented each
encounter, barrier, and action taken on standardized
tracking logs developed based on the needs assessment
of our targeted population. Our needs assessment
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who delayed abnormal screen follow-up and focused on
identification of personal and system barriers to care
[29]. Using the VA's comprehensive computerized
patient record system, trained research assistants
performed chart audits for clinical outcomes data fol-
lowing national PNRP guidelines [13]. Teams of re-
searchers (N.N., P.B., T.L., and E.R.) independently
abstracted data on a subset of the entire sample and it-
eratively compared results until they achieved consistent
agreement; clinical co-investigators (M.S. and J.M.) adju-
dicated discrepancies. The project and data managers
thoroughly reviewed data completeness and cleaned
entry errors on a quarterly basis.
Outcome measures
The primary outcome for the prostate screening group
was time from abnormal screening test to diagnostic
resolution (Time 1). For the prostate cancer diagnosis
group, the primary outcome was time from diagnostic
resolution to treatment initiation (Time 2). These events
had to occur before 365 days from abnormal screen for
Time 1 or 365 days from diagnosis for Time 2 to be
considered events in the statistical analysis. Otherwise,
they were censored at 365 days. Abnormal screening
was defined as the date of the abnormal prostate screen-
ing test (PSA or DRE) prompting referral for follow-up,
and definitive diagnosis was defined as the date of the
diagnostic test (transrectal ultrasound (TRUS)-guided bi-
opsy or follow-up PSA test) resolving the screening test
into a cancer diagnosis or non-cancer diagnosis (nega-
tive biopsy on pathology or normal PSA level/velocity
for those who resolved with a follow-up PSA test).
Treatment initiation was defined as the first date of
treatment receipt with single or combination therapy
(surgery, radiation, hormonal therapy, cryotherapy, or
decision to watch and wait).
Statistical analysis
Based on preliminary data and our group’s clinical ex-
perience with veterans with prostate cancer, we esti-
mated that the mean time from abnormal screen to
diagnostic resolution (Time 1) in the control group
would be 103 days, and the mean time from cancer diag-
nosis to treatment initiation (Time 2) in cancer patients
would be 128 days. The initial power calculation indi-
cated that for Time 1, 300 patients per group would
have 80% power to detect a mean Time 1 of 86 days in
the navigated group, and that 120 cancer patients per
group would have 80% power to detect a mean Time 2
of 90 days in the navigated group. Since only 245 instead
of 300 patients were enrolled per group for Time 1, the
actual effect size for Time 1 that was detectable with
80% power was 103 days versus 84 days. Since only 85instead of 120 patients were enrolled per group for Time
2, the actual effect size for Time 2 that was detectable
with 80% power was 128 days versus 82 days. Two-tailed
tests and a Type I error rate of 5% were assumed.
All statistical analyses were conducted using SAS ver-
sion 9.2 (SAS Institute, Inc., Cary, North Carolina) [31].
For categorical variables, frequencies and percentages
were calculated by group and for the whole sample.
Comparisons between groups were made using Fisher’s
exact test. Unadjusted and adjusted time-to-event ana-
lyses were done for Time 1 and Time 2. For unadjusted
analyses, Kaplan-Meier curves were calculated, median
times (25th percentile for one analysis since the median
was not attained) within groups were determined from
these curves, and curves were compared between groups
using the log-rank test. For adjusted analyses, propor-
tional hazards regression was used. The proportional
hazards assumption was assessed by inclusion of a group
by log-time interaction term. For Time 1, age (< 65, ≥ 65),
and race (African American, non-African American) were
used as covariates. Baseline absolute PSA value was not in-
cluded in the model, as nearly one-fifth of patients were
eligible based on an abnormal DRE or PSA velocity. For
Time 2, age (< 65, ≥ 65), race (African American, non-
African American), and total Gleason score (≤ 6, > 6) were
used as covariates. Adjusted hazard ratios (HR) and 95%
confidence intervals are reported, together with a p-value
testing whether the HR was 1.0. A HR greater than 1 indi-
cated that the outcome occurred earlier in the navigated
group compared with the control group. A HR less than 1
indicated that the outcome occurred later in the navigated
group compared with the control group. Kaplan-Meier
curves showed a crossover time point, an indication that
the proportional hazards assumption might be violated;
thus, time to event was analyzed separately before the
cross-over period in each analysis. A significant group by
log-time interaction (p = 0.0009) indicated the propor-
tional hazards assumption did not hold for Time 1. For
Time 1, navigated and control groups were then compared
(a) using all participants in the analysis and censoring
everyone with a follow-up time greater than 80 days and
(b) using only those participants with follow-up greater
than 80 days. The proportional hazards assumption did
hold for Time 2. For Time 2, navigated and control groups
were compared within subgroups determined by: (a)
Gleason score (≤ 6 vs. > 6); (b) treatment type; and (c) re-
ceipt of consultation beyond a urologist, given that mul-
tiple specialist visits could delay treatment initiation.
Results
Study participants
Figure 1 presents a flow chart of patient progression
through the study. Of the 490 study participants, 245
were enrolled in each of the control and patient
Figure 1 Prostate navigation study flow chart. The chart shows the flow of patients through the study, including the proportion who reached
a diagnostic resolution and treatment initiation and those who were censored. Abbreviations: PSA, prostate specific antigen; DRE, digital rectal
exam; VA, Veterans Affairs hospital; aEligibility types: (1) elevated PSA, PSA≥ 4.0 nanograms/milliliter (ng/mL); (2) PSA < 4.0 ng/mL with an
abnormal velocity; (3) abnormal DRE.
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Time 2, reasons for censoring are tabulated for each
study group. Of the 490 patients, 414 reached diagnostic
resolution and are considered events in the time-to
-event analysis of Time 1. Of the 170 patients diagnosed
with cancer, 154 initiated treatment and are considered
events in the analysis of Time 2.
Baseline participant characteristics are reported in
Table 1. Almost all patients (92%) were eligible based on
an abnormal PSA test, 47% were at least 65 years old,
two-thirds were African American, and 86% had a low
Charlson Comorbidity Index [32] score (0-2). There were
significant differences between control and navigated par-
ticipants in age (p < 0.05), race/ethnicity (p < 0.0001), and
baseline PSA (p = 0.008). Among the 170 patients diag-
nosed with cancer, half were at least 65 years old, 69%
were African American, and 57% had a Gleason scoregreater than 3 + 3 (Table 2). A total of 213 patients refused
to participate in navigation, many citing lack of time as
the reason.
Time to diagnostic resolution
Among our total sample, 85% reached a diagnostic reso-
lution (50% with a negative resolution based on a nega-
tive biopsy or repeat PSA test; 35% with a positive
diagnosis) (Table 1). Seventy-six (16%) were unresolved
(Figure 1). Resolution rates were comparable between
the study groups.
With respect to Time 1, navigated patients had a diag-
nostic test completion rate of 211 events among 245 pa-
tients versus 203 events among 245 control patients.
Navigation did not significantly affect time to diagnostic
resolution compared to controls (median days of 97 ver-
sus 111; adj. HR 1.17, 95% CI, 0.96 – 1.43, p = 0.12).






N (%) N (%)
Age 0.046
< 65 years old 142 (58) 119 (49)
≥ 65 years old 103 (42) 126 (51)
Range 48-79 42-92
Race/ethnicity <0.0001
African American 155 (63) 177 (72)
White 68 (28) 37 (15)
Other 20 (8) 7 (3)
Not reported 2 (1) 24 (10)
Comorbidities (CCI Score) 0.72
0 96 (39) 90 (37)
1-2 114 (47) 123 (50)
> 2 35 (14) 32 (13)
Screening eligibility 0.058
PSA test (≥ 4.0 ng/mL) 204 (83) 210 (86)
Abnormal PSA velocity 26 (11) 13 (5)
Abnormal (DRE) 15 (6) 22 (9)
Baseline PSA 0.011
< 4 ng/mLa 26 (11) 11 (5)
4 ng/mL - 10 ng/mL 164 (71) 154 (69)
> 10 ng/mL 40 (17) 58 (26)
Missing (Eligible by DRE) 15 (6) 22 (9)
Cancer diagnosis 0.54
No cancer/resolved with PSA test 127 (52) 117 (48)
Cancer 84 (34) 86 (35)
Unresolved 34 (14) 42 (17)
Abbreviations: CCI, Charlson Comorbidity Index; PSA, prostate specific antigen;
ng/mL, nanogram per milliliter; DRE, digital rectal exam.
aValues may not sum to all subjects who enrolled on abnormal PSA velocity
due to rounded PSA value.







N (%) N (%)
Age 0.17
< 65 years old 47 (56) 39 (45)
≥ 65 years old 37 (44) 47 (55)
Range 50-79 43-92
Race/ethnicity 0.011
African American 53 (63) 64 (74)
White 23 (27) 13 (15)
Other 7 (8) 2 (2)
Not reported 1 (1) 7 (8)
Gleason score 0.008
≤ 3 + 3 45 (54) 28 (33)
> 3 + 3 39 (46) 58 (67)
Consultation beyond Urologya 0.36
Yes 35 (42) 42 (49)
No 49 (58) 44 (51)
Primary Therapy 0.45
Prostatectomy 26 (30) 24 (28)
External Radiation Therapy 14 (17) 13 (15)
Hormone Therapy 17 (20) 28 (33)
Watchful Waiting 15 (18) 14 (28)
Interstitial Radiation Therapy 2 (2) 0 (0)
Cryotherapy 1 (1) 0 (0)
Treatment not initiated 9 (11) 7 (8)
aConsultation with radiation oncologist, medical oncologist, or surgeon.
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point; thus, time to event was analyzed separately before
80 days (using the total sample size and censoring
follow-up times greater than 80 days) and after the
80 days (using those with follow-up greater than 80 days).
Prior to 80 days, the 25th percentile of the time to diag-
nostic resolution was not significantly different between
the navigated and control groups (25th percentile of
68 days versus 55 days, p = 0.45, Table 3). The adjusted
HR was 0.91 (p = 0.53). Beyond 80 days, median time to
diagnostic resolution was significantly shorter among the
navigated group compared to the control group (median
of 151 days versus 190 days, p = 0.015). The adjusted HR
was 1.41 (p = 0.01).
In the analysis of Time 1 by race (African American,
White), outcomes were similar to overall results. Priorto 80 days, the 25th percentile of the time to diagnostic
resolution was similar in the navigated and control
groups within each racial group (data not shown). Be-
yond 80 days, the median time to diagnostic resolution
was shorter among the navigated group within each ra-
cial group, and significant among White participants
(median of 122 days versus 179 days, p = 0.047).
Time to treatment initiation
Among patients diagnosed with cancer, 16 (9%) did not
initiate treatment after diagnosis (Table 2 and Figure 1).
With respect to Time 2, navigated patients had a treat-
ment initiation rate of 75 events among 84 patients versus
79 events among 86 control patients (Table 3). Median
time to treatment initiation was 93 days in the navigated
group and 87 days in the control group, p = 0.36. The ad-
justed HR was 1.15 (p = 0.41). Kaplan-Meier curves are il-
lustrated in Figure 3.
In the analysis of Time 2 by race (African American,
White), results were similar to the overall results: no
navigated-control differences in time to treatment
Figure 2 Time to diagnostic resolution (Time 1) Kaplan-Meier
survival curves. The curves illustrate the proportion of navigated and
control patients who did not resolve an abnormal prostate cancer
screening test within one year. Time (days) to event (resolution) was
analyzed separately before and after the crossover time point.
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addition, we found no difference in navigated versus con-
trol group median days to treatment initiation with re-
spect to Gleason score or consultation beyond a urologist
(data not shown). With respect to treatment types, no dif-
ference was observed except among men whose primary
therapy was radiation, where time to treatment initiation
was significantly lower for navigated versus control group
participants (median of 95 days versus 120 days, p = 0.05).
Discussion
In our study, we found no overall effect of patient navi-
gation on time to diagnostic resolution or time to treat-
ment initiation among veterans with an abnormal prostate
cancer screening test or cancer diagnosis, respectively, re-
gardless of race.
Several possible explanations for our findings exist.
First, our intervention may have missed the crucial time






Time 1: Time from abnormal screening to diagnostic resolution
Time 1 stratified by diagnostic
resolution time interval
0-80 days Navigated 245 95 (3
Control 245 96 (3
81-365 days Navigated 146 116 (7
Control 148 107 (7
Time 2: Time from diagnostic resolution to treatment initiation
Time 2 overall 0-365 days Navigated 84 75 (8
Control 86 79 (9
Abbreviations: H.R. hazard ratio.
aFor Time 1, age (< 65, ≥ 65) and race (African American, non-African American) we
African American), and Gleason score (≤ 6, > 6) were used as covariates.
b25th percentile since median not attained.trial based at public hospitals, Bastani et al. found that
women who missed their first appointment following an
abnormal breast screening had no chance of timely diag-
nostic resolution [33]. She posited that clinic staff may
have been more invested in ensuring that women who
kept their first appointment understood the follow-up
process, resulting in better appointment adherence
downstream. Men in our study had already kept their
first follow-up appointment in the urology clinic, the
first opportunity presented to obtain written informed
consent, which may have similarly accounted for the ab-
sence of overall navigation effect. Our VA also included
other well-established support mechanisms, such as the
urology clinic nurse practitioner who provided prostate
cancer education and volunteer clinic staff who performed
appointment reminders. Finally, though we anticipated
gender-matched navigation would facilitate communi-
cation, male patients have demonstrated less receptivity
to social support in the clinical setting than women [34],
which additionally could have diminished the interven-
tion’s effect.
Though the overall finding for time to resolution was
negative, navigated patients who did not reach diagnos-
tic resolution within the first 80-day period resolved
their screening test faster than controls. This shortened
time may be attributed to factors inherent to navigation:
the establishment of trust, access to education and infor-
mation, and decreased anxiety. Men who delay diagnos-
tic resolution beyond a 3-month period may merit
outreach via patient navigation. In subgroup analyses
among participants with prostate cancer, navigated men
whose primary therapy was radiation had a shorter time
to treatment than controls. Further research to better
delineate the navigators’ role in supporting men through
the complex treatment decision making process is needed.
Study limitations include, first, a lack of individual
randomization to participate in navigation. We initially





Adj. H.R.a Adj. 95% C.I. Adj. p-value
8.8%) 68b 0.91 0.53
9.2%) 55b 0.45 0.67 – 1.23
9.4%) 151 1.41 0.01
2.3%) 190 0.015 1.07 - 1.86
9.3%) 93 1.15 0.41
1.9%) 87 0.36 0.82 - 1.62
re used as covariates. For Time 2, age (< 65, ≥ 65), race (African American, non-
Figure 3 Time to Treatment Initiation (Time 2) Kaplan-Meier
Survival Curves. The curves illustrate the proportion of navigated and
control patients who did not initiate prostate cancer treatment within
one year of diagnosis. Time (days) to event (treatment initiation) was
analyzed separately before and after the crossover time point.
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and the other as the control site; however, a hospital
merger just prior to accrual made this design logistically
unfeasible. We ultimately chose to assign navigation
based on clinic day to allow for minimal disruption to
patient care during clinic reconfiguration and to reduce
contamination between study arms at the single clinic
site. While enrolling navigated patients and contempor-
aneous controls on designated clinic days could lead to
selection bias, all patients were selected from the same
clinic at one VA location and cared for by physicians
with similar practice patterns. Second, we acknowledge
that the differences in race between our control and nav-
igated groups may have been due to use of administra-
tive data versus self-reported race/ethnicity data,
respectively, in each arm—two different methods show-
ing low agreement in other VA studies [35,36]. Third,
our findings may not be generalizabile to non-VA hospi-
tals and non-VA male populations. Fourth, our outcome
measures focused on time may not have targeted the
true value of prostate cancer navigation. Finally, referral
bias remains a concern, since patients referred to a study
tend to be more motivated about their health.
Despite limitations, this study is the first controlled
navigation intervention that elucidates prostate cancer
outcomes at a VA. The Denver PNRP implemented their
intervention in an integrated safety-net health care sys-
tem and found that prostate cancer navigation shortened
time to diagnostic resolution, with borderline significant
results attributed to a small sample size and potential re-
duced screening practice among older age groups [19]. By
contrast, our VA routinely screened veterans including
older men and those with chronically elevated PSA tests,
which may have conferred less urgency to fast-track them
through the referral process. Furthermore, insufficientevidence supporting negative long-term effects of diagnos-
tic or treatment delays on biochemical progression [37,38]
or survival [39] could have also reduced urgency within
our cancer group.Conclusions
In summary, our study indicated that patient navigation
did not significantly reduce time to diagnostic resolution
among men with an abnormal prostate cancer screen or
treatment initiation among men with prostate cancer.
Targeting patients who miss their first follow-up appoint-
ment after identification of abnormal finding may have
more optimally impacted time-related outcomes. Notably,
prostate cancer is the second most frequently diagnosed
cancer among American men yet holds the most controver-
sial track record for screening and has a range of treatment
options, including the choice to not pursue treatment. It is
therefore imperative that emerging navigation programs
consider their impact on additional parameters beyond
timelier care, such as quality of life and treatment decision
making, to address prostate cancer disparities.
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